Document Detail


Treatment options for prehypertension.
MedLine Citation:
PMID:  17420669     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Prehypertension is a recognized stage of blood pressure but treatment standards have not yet been established. This review will focus on the treatment considerations in prehypertension.
RECENT FINDINGS: Previous approaches to prehypertensive blood pressure have focused on the role of nonpharmacologic modalities alone. The recently published Trial of Preventing Hypertension (TROPHY) is the first study of pharmacologic intervention in this category of blood pressure.
SUMMARY: TROPHY forged new territory in the area of pharmacologic treatment for prehypertension. The safety and tolerability of the angiotensin receptor blocker treatment in the trial offer a new option to clinicians attempting to avoid the ravages of hypertension in the patients they treat. Furthermore the stage is properly set for additional research in treatments for prehypertension.
Authors:
Shawna D Nesbitt
Related Documents :
16793939 - Modeling baroreflex regulation of heart rate during orthostatic stress.
1593299 - The j-shaped curve in elderly hypertensives.
873659 - Psychological test and demographic variables associated with retention of narcotic addi...
11721219 - A review of hypertension in the elderly.
3544829 - Hypertension in the elderly.
1483799 - Treatment of high altitude diseases without drugs.
7733089 - Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effe...
426949 - Baroreflex sensitivity in hypertension during beta-adrenergic blockade.
15535059 - Thoracic gas volume measurements in paralyzed mice.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current opinion in nephrology and hypertension     Volume:  16     ISSN:  1062-4821     ISO Abbreviation:  Curr. Opin. Nephrol. Hypertens.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-10     Completed Date:  2007-06-07     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9303753     Medline TA:  Curr Opin Nephrol Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  250-5     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8899, USA. Shawna.Nesbitt@utsouthwestern.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / pharmacology,  therapeutic use*
Antihypertensive Agents / pharmacology,  therapeutic use*
Benzimidazoles / therapeutic use
Blood Pressure / drug effects*
Diet
Disease Progression
Exercise
Humans
Hypertension / epidemiology,  physiopathology,  prevention & control*
Incidence
Life Style*
Practice Guidelines as Topic
Tetrazoles / therapeutic use
Grant Support
ID/Acronym/Agency:
R01 HL72427-01/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Tetrazoles; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Understanding estimated glomerular filtration rate: implications for identifying chronic kidney dise...
Next Document:  Antihypertensive medications and risk of diabetes mellitus.